[Cl:1][C:2]1[CH:3]=[C:4]([CH:13]=[C:14]([Cl:16])[CH:15]=1)[CH2:5][N:6]1[CH:10]=[CH:9][N:8]=[C:7]1[CH:11]=O.C([C:19]1[CH:37]=[CH:36][CH:35]=[CH:34][C:20]=1[C:21]([CH2:32][CH3:33])(CC)OP(CC([O-])=O)(O)=O)C.[Li+].[OH-:39].C1C[O:43][CH2:42][CH2:41]1>>[CH2:42]([O:43][C:33](=[O:39])[C:32]([CH2:21][C:20]1[CH:19]=[CH:37][CH:36]=[CH:35][CH:34]=1)=[CH:11][C:7]1[N:6]([CH2:5][C:4]2[CH:3]=[C:2]([Cl:1])[CH:15]=[C:14]([Cl:16])[CH:13]=2)[CH:10]=[CH:9][N:8]=1)[CH3:41]To a solution of 1-(3,5-dichloro-benzyl)-1H-imidazole-2-carbaldehyde (see Example 2) (0.59 g, 2.33 mmol) and triethyl-2-benzylphosponoacetate (0.81 g, 2.58 mmol) (prepared according to J. Med. Chem. 1993, 36, 87-94) in dry THF (3 mL) was added LiOH (62 mg, 2.58 mmol). The mixture was stirred for 14 h at ambient temperature then partitioned with water (20 mL) and EtOAc (40 mL). The organic layer was collected, washed with brine, dried over MgSO4 and concentrated in vacuo. The material was purified by column chromatography (silica gel, 100% diethyl ether) to provide 2-benzyl-3-[1-(3,5-dichloro-benzyl)-1H-imidazol-2-yl]-acrylic acid ethyl ester (0.41 g, 42%) as a colorless oil: ESI MS m/z 415 [C22H20Cl2N2O2+H]+.
読み込み中…